: Attachment J b oO 2 fo )
Special 5100K) Summary
: es
UltraLight If Nd:YAG Laser System
This 510(K) Summary of safety and effectiveness for the UltraLight II Nd:YAG Laser System
is submitted in accordance with the requirements of the SMDA. 1990 and following guidance concerning the
organization and content of a 510(K) summary. :
Applicant: Sandstone Medical Technologies, LLC
Address: Sandstone Medical Technologies LLC FEB 3 2009
516 Scott Street
. Homewood, AL 35209 USA
Contact Person: Mr. Mark Rohrer
Telephone: 1-205-290-8251— Phone
Preparation Date: August 20, 2008
. Device Trade Name: UltraLight IT Nd:YAG Laser System
Common Name: Nd:YAG Laser System
/ Classification Name: Instrument, Surgical, Powered, laser ‘
79-GEX, 21 CFR 878-48 : .
Legally Marketed Predicate Device: UltraLight I Nd:YAG Laser System
; K041011
Description of the UltraLight I Nd: VAG The UltraLight If Nd:YAG Laser System consists of a power
Laser System: ° supply unit with cooling, a footswitch and an umbilical cord
that connects to the laser, which is located in the handpiece.
In standard use, the handpiece is held against the treatment
, area dn the light pulse is delivered when the footswitch is
. depressed. Laser parameters and other system features are
. controlled from the display panel located on the front of the
power supply unit.
Intended use of the UltraLight I Nd:YAG At the 1064 nm wavelength — dark ink tattoo removal, removal of
Laser System: pigmented lesions and the removal or lightening of hair.

: At the 532 nm wavelength -- removal of red ink tattoos, treatment
of vascular lesions including facial and leg veins, telangiectasis,
angiomas, hemangiomas, port wine stains and most pigmented
lesions (e.g. lentigines, ephildes)

Performance Data: None
Results of Clinical Study: None :
Conclusion: The UltraLight II Nd:YAG laser system is substantially equivalent
to other existing Nd:YAG Laser Systems in commercial
distribution for use in Dermatology and Plastic Surgery.
1-1

fy, DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
9 RN
“nals / Food and Drug Administration
9200 Corporate Boulevard
. Rockville MD 20850
Sandstone Medical Technologies, LLC mr:
% Mr. Mark Rohrer FEB ~ § 2008 Coe
, 105 Citation Court =
Homewood, Alabama 35209 : :
Re: K082407 .
Trade/Device Name: Sandstone Medical Technologies UltraLight I] Nd:YAG Laser
‘ System ,
- Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery
and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: January 13, 2009
Received: January 14, 2009Dear Mr. Rohrer: 7 oe
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
. commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration. ;
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
~ that FDA has made a determination that your device complies with other requirements of the Act _
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
. CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

Page 2 — Mr. Mark Rohrer . .
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic ,
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) ,
premarket notification. ‘The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
‘ If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance at
(240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification” (21CFR Part 807.97). For questions regarding postmarket surveillance,
_ please contact CDRH’s Office of Surveillance and Biometric’s (OSB’s) Division of Postmarket
Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events
(Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems
at (240) 276-3464, You may obtain other general information on your responsibilities under the
Act from the Division of Small Manufacturers, International and Consumer Assistance
at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address ‘
http://www. fda. gov/cdrh/industry/support/index. html.
: Sincerely yours,
/ Mark N. Melkerson
/ Director . ‘
Division of General, Restorative
and Neurological Devices .
Office of Device Evaluation : .
Center for Devices and
: Radiological Health :
Enclosure / : ‘
. a .

indications for Use
koszye] |
— .
510(k) Number (if known): _K Pending oo
‘Device Name: Sandstone Medical Technologies UltraLight I Nd:YAG
Laser System
Indications For Use:

* At the 1064 nm wavelength — dark ink tattoo removal, removal of pigmented lesions
and the removal or lightening of hair. ‘

® At the $32 nm wavelength — removal of red ink tattoos, treatment of vascular lesions
including facial and leg veins, telangiectasias, angiomas, hemangiomas, port wine
stains and most pigmented lesions (c.g. lentigines, ephildes)

Prescription Use xx AND/OR Over-The-Counter Use ,
> (Part 24 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED) :
. Concurrence of CDRH, sake (ODE)
- Divisi*.: of General, Restorative,
and Ncxcological Devices
. : . Page 1 of 1 ,
310K) Number LOY

